Litigation Details for BAYER SCHERING PHARMA AG v. BARR PHARMACEUTICALS, INC. (D.N.J. 2005)

BAYER SCHERING PHARMA AG v. BARR PHARMACEUTICALS, INC. (D.N.J. 2005)

Docket		Date Filed	2005-04-29
Court	District Court, D. New Jersey	Date Terminated	2008-03-03
Cause	28:1338 Copyright Infringement	Assigned To	Peter G. Sheridan
Jury Demand	Both	Referred To	Esther Salas
Parties	BARR PHARMACEUTICALS, INC.
Patents	6,787,531
Attorneys	WILLIAM J. O'SHAUGHNESSY
Firms	McCarter & English, LLP
Link to Docket	External link to docket

Details for BAYER SCHERING PHARMA AG v. BARR PHARMACEUTICALS, INC. (D.N.J. 2005)

Date Filed	Document No.	Description	Snippet	Link To Document
2005-04-29				External link to document

# Bayer Schering Pharma AG v. Barr Pharmaceuticals, Inc. (2:05-cv-02308): Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Bayer Schering Pharma AG’s litigation against Barr Pharmaceuticals concerned Barr’s abbreviated new drug application (ANDA) for a generic version of Yasmin, Bayer’s drospirenone and ethinyl estradiol oral contraceptive. The dispute centered on U.S. Patent No. 6,787,531, which covered pharmaceutical compositions containing micronized drospirenone and ethinyl estradiol. The U.S. District Court for the District of New Jersey held the asserted claims invalid for obviousness. The Federal Circuit affirmed in 2009, ending Bayer’s patent-based barrier to Barr’s generic product.[1]

What drugs and patents were involved in Bayer v. Barr?

The case involved Yasmin, a combined oral contraceptive containing:

Product	Active ingredients	Dosage associated with litigation	Regulatory pathway
Yasmin	Drospirenone and ethinyl estradiol	3 mg drospirenone / 0.03 mg ethinyl estradiol	NDA
Barr’s proposed generic	Drospirenone and ethinyl estradiol	Equivalent or substantially equivalent oral contraceptive formulation	ANDA

The asserted patent was U.S. Patent No. 6,787,531, titled “Pharmaceutical composition containing drospirenone and ethinylestradiol.” The patent addressed the combination of drospirenone and ethinyl estradiol in an oral contraceptive composition, including the use of micronized drospirenone.[1]

What was the asserted patent’s commercial purpose?

Drospirenone is a synthetic progestin used with ethinyl estradiol in combined oral contraceptives. Bayer’s formulation strategy sought to deliver drospirenone in a form that would provide suitable oral bioavailability while maintaining the desired contraceptive dosage.

The patent did not claim a new molecular entity. Its value depended on formulation and composition protection around an established contraceptive combination. That distinction mattered in the obviousness analysis because the court evaluated whether the claimed formulation would have been an expected result of applying known pharmaceutical techniques.

What was the litigation timeline in Bayer Schering Pharma v. Barr?

Date	Event
1998	Priority period associated with the claimed drospirenone and ethinyl estradiol formulation
September 7, 2005	Bayer filed the District of New Jersey action, docket No. 2:05-cv-02308
2005-2008	Litigation proceeded over Barr’s ANDA and the validity and enforceability of the ’531 patent
2008	District court ruled that the asserted claims were invalid for obviousness
August 6, 2009	Federal Circuit issued its decision affirming the district court
2009	The Federal Circuit judgment removed the principal patent obstacle to Barr’s generic launch

The case arose under the Hatch-Waxman framework. Barr’s ANDA filing included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product. Bayer’s infringement action triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the litigation’s resolution and applicable regulatory events.[2]

What did the District Court decide?

The District Court held the asserted claims of the ’531 patent invalid for obviousness under 35 U.S.C. § 103. The court concluded that the claimed composition was an obvious development based on the prior art and the ordinary skill of pharmaceutical formulators.[1]

The analysis focused on whether a skilled artisan would have been motivated to combine drospirenone and ethinyl estradiol in the claimed dosage form and whether the use of micronized drospirenone would have been an expected formulation choice.

The district court rejected Bayer’s argument that the claimed formulation produced sufficiently unexpected results to preserve validity. It found that the asserted claims did not reflect an inventive step sufficient to overcome the prior art.

Why did the Federal Circuit affirm the obviousness ruling?

The Federal Circuit affirmed the district court’s judgment in Bayer Schering Pharma AG v. Barr Pharmaceuticals, Inc., 575 F.3d 1341 (Fed. Cir. 2009).[1]

What prior-art reasoning controlled the appeal?

The Federal Circuit treated the case as a conventional obviousness dispute involving:

1. The scope and content of the prior art.
2. The differences between the prior art and the asserted claims.
3. The level of ordinary skill in pharmaceutical formulation.
4. Secondary considerations, including unexpected results.

The Federal Circuit concluded that the district court had sufficient evidence to find the claimed formulation obvious. The prior art disclosed the relevant contraceptive ingredients and provided a basis for selecting the claimed combination and dosage approach. The use of micronized drug particles was also within the technical options available to a skilled formulator.

How did the court treat unexpected results?

Bayer relied on evidence that the claimed formulation provided improved or useful pharmacokinetic performance. The Federal Circuit held that the evidence did not overcome the strong obviousness case established by the prior art.

The court’s treatment of unexpected results is significant for formulation patents. Evidence of improved dissolution, absorption, or bioavailability must be tied closely to the full scope of the claims. A result that is unexpected for one formulation or dosage condition may not establish nonobviousness across broader claims.

The decision also illustrates that routine optimization remains vulnerable when the prior art identifies the relevant active ingredients, dosage range, delivery form, and formulation objective.

What patent claims were at risk?

The asserted claims covered compositions containing drospirenone and ethinyl estradiol, with limitations directed to the drug amounts and formulation characteristics. The patent’s commercial protection depended on the combined effect of:

• The two active pharmaceutical ingredients.
• The oral dosage form.
• The selected dosage amounts.
• The physical form or particle-size treatment of drospirenone.
• The resulting pharmaceutical performance.

The Federal Circuit’s affirmance invalidated the asserted claims on obviousness grounds. The ruling therefore eliminated the enforceable patent protection that Bayer had asserted against Barr’s ANDA product.

What was the Paragraph IV challenge?

Barr’s Paragraph IV certification alleged that the relevant Bayer patent was invalid, unenforceable, or not infringed. Bayer responded by filing a patent-infringement action in the District of New Jersey.

A Paragraph IV filing is not an admission of infringement. It is a statutory mechanism that allows an ANDA applicant to challenge listed patents before commercial launch. Once the brand company files suit within the statutory period, FDA approval is generally subject to the 30-month stay, unless the stay is shortened or otherwise affected by court action.

The case is an example of the commercial importance of Paragraph IV litigation for formulation patents. A successful invalidity ruling can allow the ANDA applicant to enter before the nominal patent expiration date.

When did the Yasmin patent lose exclusivity?

The ’531 patent lost practical exclusivity when the courts determined that the asserted claims were invalid. The Federal Circuit’s 2009 affirmance was the controlling appellate event.

Patent expiration and enforceability are separate issues:

Exclusivity issue	Effect in this case
Statutory patent term	Set a nominal expiration date based on the patent’s filing and priority history
Patent validity	Defeated by the obviousness ruling
Patent enforceability	The appellate decision did not preserve the asserted claims
FDA approval delay	Controlled by Hatch-Waxman litigation rules and regulatory exclusivity
Commercial generic entry	Became possible after the patent litigation barrier was removed

The case did not establish a surviving patent right that could block Barr after the Federal Circuit judgment. Any separate patents covering other drospirenone products, dosing regimens, packaging, or formulations required independent analysis.

What was the Orange Book status of Yasmin?

Yasmin was marketed under an FDA-approved new drug application, and Hatch-Waxman patent listing rules were central to the dispute. The case involved an ANDA applicant challenging a listed patent associated with Bayer’s product.

The litigation should not be read as establishing that every patent associated with Yasmin was invalid. The decision addressed the asserted claims of the ’531 patent. Orange Book listings can include patents directed to active ingredients, formulations, methods of use, or other approved-product attributes. Each listing requires separate review for claim scope, expiration, certification, and enforceability.[2]

Did the case involve a method-of-use patent?

The reported Federal Circuit decision focused on the composition and formulation claims of the ’531 patent. It was not primarily a method-of-use dispute. The case therefore provides stronger guidance on formulation obviousness than on the enforceability of contraceptive-use claims.

What formulation patents are vulnerable under Bayer v. Barr?

Bayer v. Barr creates a material risk for formulation patents when the patent claims a predictable combination of known elements. Risk increases where:

• The active ingredients are already known.
• The claimed dosage is within a disclosed or routine range.
• Micronization, particle-size reduction, or excipient selection is conventional.
• The formulation objective is improved dissolution or bioavailability.
• The patent relies on results that are not demonstrated across the full claim scope.
• The specification does not establish a technical reason to reject known alternatives.

The decision does not mean all formulation patents are weak. A formulation patent may remain strong where it demonstrates a nonroutine manufacturing process, an unexpected interaction between ingredients, a narrow and technically critical particle-size distribution, or a clinically meaningful result that could not reasonably have been predicted.

How strong was Bayer’s patent estate after the decision?

The litigation materially weakened Bayer’s protection for the asserted Yasmin formulation. The principal patent in suit could no longer be used to block Barr’s ANDA product.

Estate component	Assessment after Federal Circuit decision
’531 composition claims	Invalidated for obviousness
Molecular patent on drospirenone	Not the basis of the reported judgment
Method-of-use claims	Not the principal subject of the appellate decision
Manufacturing patents	Not resolved by the reported judgment
Regulatory exclusivity	Separate from patent validity
Brand differentiation	Dependent on product recognition, regulatory status, and commercial execution

The case demonstrates the difference between a broad product franchise and a durable patent estate. A branded product can have substantial sales while relying on a relatively narrow formulation patent. If that patent is invalidated, later-filed or separately listed patents must carry the remaining protection.

Which companies were challenging Bayer’s contraceptive franchise?

Barr was the defendant and ANDA challenger in this action. Barr later marketed generic drospirenone and ethinyl estradiol products, including the product associated with the generic Yasmin market.

The broader competitive field included other generic manufacturers pursuing oral contraceptive products containing drospirenone and ethinyl estradiol. The case itself, however, does not establish the litigation positions or entry dates of every later generic applicant.

Bayer’s Yaz franchise also involved related products and patents distinct from the Yasmin dispute. Patent analysis must separate:

• Yasmin from Yaz.
• Different ethinyl estradiol strengths.
• Different labeling and indications.
• Different patents and Orange Book listings.
• Different ANDA applicants and litigation outcomes.

Did biosimilar risk apply to this case?

No. Biosimilar risk was not relevant because Yasmin is a small-molecule drug, not a biologic. Barr proceeded under the ANDA pathway, not the biosimilar pathway established under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• Paragraph IV invalidity challenges.
• Generic approval after the Hatch-Waxman stay.
• Early generic launch after patent defeat.
• Substitution and price erosion in the oral contraceptive market.

Did the parties settle?

The reported Federal Circuit decision reflects an adjudicated invalidity ruling rather than a settlement disposition. The appellate court affirmed the district court’s judgment that the asserted patent claims were invalid.

The decision does not provide a basis for treating the case as a conventional reverse-payment settlement. The operative legal result was a judgment on patent validity.

What were the commercial consequences for Bayer and Barr?

The judgment removed Bayer’s asserted patent barrier to Barr’s generic product. The principal commercial effects were:

1. Barr gained a path to generic entry before the nominal expiration of the invalidated claims.
2. Bayer faced generic price competition for the Yasmin product.
3. The value of the ’531 patent dropped from an enforceable exclusion right to an invalidated asset.
4. Future commercial protection depended on other patents, regulatory exclusivity, brand loyalty, and product differentiation.

The reported opinions do not quantify Bayer’s lost revenue, Barr’s launch sales, or damages. They establish the legal outcome, not a financial valuation.

What generic launch risks existed after the ruling?

After the Federal Circuit affirmed invalidity, the primary patent risk to Barr’s launch was substantially reduced. Remaining risks could have included:

• FDA approval requirements.
• ANDA deficiencies or regulatory delay.
• Other unasserted or separately listed patents.
• Labeling differences.
• Manufacturing and supply constraints.
• Additional litigation involving related products or patents.

The case therefore supported a high-confidence patent clearance position for the asserted ’531 claims, but it did not provide a blanket clearance opinion for every Bayer contraceptive product or every patent in the broader franchise.

Key Takeaways

• Bayer sued Barr after Barr filed a Paragraph IV ANDA challenge involving a generic Yasmin product.
• The principal patent was U.S. Patent No. 6,787,531.
• The patent covered a drospirenone and ethinyl estradiol pharmaceutical composition, including micronized drospirenone.
• The District of New Jersey held the asserted claims invalid for obviousness.
• The Federal Circuit affirmed in 2009 in 575 F.3d 1341.
• The case weakened Bayer’s formulation-based exclusivity for Yasmin.
• The decision is important for pharmaceutical formulation patents relying on routine micronization, dosage selection, and expected bioavailability improvements.
• This was a small-molecule ANDA case, not a biosimilar dispute.
• The reported decision reflects adjudicated patent invalidity, not a settlement-based entry arrangement.
• Invalidity of the ’531 patent did not automatically invalidate every patent associated with Yasmin, Yaz, or related drospirenone products.

FAQs

What was the main patent in Bayer Schering Pharma AG v. Barr?

The main patent was U.S. Patent No. 6,787,531, directed to a pharmaceutical composition containing drospirenone and ethinyl estradiol.

Did Barr win the Yasmin patent case?

Yes. Barr prevailed on patent validity. The asserted claims were held invalid for obviousness, and the Federal Circuit affirmed.

Was Bayer v. Barr an Orange Book patent case?

Yes. The dispute arose from an ANDA and Paragraph IV challenge involving a patent listed in connection with Bayer’s approved oral contraceptive product.

Did Bayer v. Barr involve Yaz or Yasmin?

The reported case concerned Yasmin-related drospirenone and ethinyl estradiol compositions. Separate Yaz products and related patents should not be treated as identical for claim-scope or exclusivity analysis.

What does Bayer v. Barr mean for micronized-drug patents?

It shows that micronization may be considered an obvious formulation step when the prior art identifies the active ingredient, dosage form, and need for adequate bioavailability. Patent strength depends on evidence of a nonroutine technical result tied to the actual claim scope.

References

1. Bayer Schering Pharma AG v. Barr Pharmaceuticals, Inc., 575 F.3d 1341 (Fed. Cir. 2009).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugsatfda.